Instituto de Investigación Sanitaria de Navarra-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2023

  1. JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology

    ACS Chemical Neuroscience

  2. JNK3 Overexpression in the Entorhinal Cortex Impacts on the Hippocampus and Induces Cognitive Deficiencies and Tau Misfolding

    ACS Chemical Neuroscience, Vol. 14, Núm. 11, pp. 2074-2088

  3. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

    Neurobiology of Disease, Vol. 183

2022

  1. Encapsulation of MSCs and GDNF in an Injectable Nanoreinforced Supramolecular Hydrogel for Brain Tissue Engineering

    Biomacromolecules, Vol. 23, Núm. 11, pp. 4629-4644

  2. Hydrogels for brain repair: application to Parkinson’s disease

    Expert Opinion on Drug Delivery, Vol. 19, Núm. 11, pp. 1521-1537

2021

  1. Blood pressure and risk of cognitive impairment: The role of vascular disease in neurodegeneration

    Brain Sciences, Vol. 11, Núm. 3

  2. Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases

    Neurological Sciences, Vol. 42, Núm. 4, pp. 1473-1482

  3. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

2020

  1. CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain

    Frontiers in Molecular Neuroscience, Vol. 13

  2. Multicenter Validation of Metabolic Abnormalities Related to PSP According to the MDS-PSP Criteria

    Movement Disorders, Vol. 35, Núm. 11, pp. 2009-2018

2019

  1. Amylin as a potential link between type 2 diabetes and alzheimer disease

    Annals of Neurology, Vol. 86, Núm. 4, pp. 539-551

  2. Cardiac sympathetic innervation in the MPTP non-human primate model of Parkinson disease

    Clinical Autonomic Research, Vol. 29, Núm. 4, pp. 415-425

  3. Nanobiotechnology in parkinson’s disease

    Nanobiotechnology in Neurodegenerative Diseases (Springer International Publishing), pp. 177-208

  4. Safinamide in clinical practice: A Spanish multicenter cohort study

    Brain Sciences, Vol. 9, Núm. 10

2018

  1. Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies

    Acta Neuropathologica, Vol. 135, Núm. 6, pp. 877-886

  2. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

    Neurobiology of Disease, Vol. 118, pp. 64-75

2016

  1. Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems

    Maturitas, Vol. 84, pp. 25-31

  2. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

  3. Development and characterization of polo-like kinase 2 loaded nanoparticles-A novel strategy for (serine-129) phosphorylation of alpha-synuclein

    International Journal of Pharmaceutics, Vol. 514, Núm. 1, pp. 142-149

2015

  1. Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: Identification of common and distinct olfactory targets across Alzheimer-related co-pathologies

    Oncotarget, Vol. 6, Núm. 37, pp. 39437-39456